CLINICAL PHARMACOLOGY
Action
DOLOBID is a non-steroidal drug with analgesic, anti-inflammatory and antipyretic properties. It is a peripherally-acting non-narcotic analgesic drug. Habituation, tolerance and addiction have not been reported.
Diflunisal is a difluorophenyl derivative of salicylic acid. Chemically, diflunisal differs from aspirin (acetylsalicylic acid) in two respects. The first of these two is the presence of a difluorophenyl substituent at carbon 1. The second difference is the removal of the 0-acetyl group from the carbon 4 position. Diflunisal is not metabolized to salicylic acid, and the fluorine atoms are not displaced from the difluorophenyl ring structure.
The precise mechanism of the analgesic and anti-inflammatory actions of diflunisal is not known. Diflunisal is a prostaglandin synthetase inhibitor. In animals, prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain. Since prostaglandins are known to be among the mediators of pain and inflammation, the mode of action of diflunisal may be due to a decrease of prosta-glandins in peripheral tissues. Pharmacokinetics and Metabolism
DOLOBID is rapidly and completely absorbed following oral administration with peak plasma concentrations occurring between 2 to 3 hours. The drug is excreted in the urine as two soluble glucuronide conjugates accounting for about 90% of the administered dose. Little or no diflunisal is excreted in the feces. Diflunisal appears in human milk in concentrations of 2-7% of those in plasma. More than 99% of diflunisal in plasma is bound to proteins.
As is the case with salicylic acid, concentration-dependent pharmacokinetics prevail when DOLOBID is administered; a doubling of dosage produces a greater than doubling of drug accumulation. The effect becomes more apparent with repetitive doses. Following single doses, peak plasma concentrations of 41 ± 11 µg/mL (mean ± S.D.) were observed following 250 mg doses, 87 ± 17 µg/mL were observed following 500 mg and 124 ± 11 µg/mL following single 1000 mg doses. However, following administration of 250 mg b.i.d., a mean peak level of 56 ± 14 µg/mL was observed on day 8, while the mean peak level after 500 mg b.i.d. for 11 days was 190 ± 33 µg/mL. In contrast to salicylic acid which has a plasma half-life of 21/2 hours, the plasma half-life of diflunisal is 3 to 4 times longer (8 to 12 hours), because of a difluorophenyl substituent at carbon 1. Because of its long half-life and nonlinear pharmacokinetics, several days are required for diflunisal plasma levels to reach steady state following multiple doses. For this reason, an initial loading dose is necessary to shorten the time to reach steady state levels, and 2 to 3 days of observation are necessary for evaluating changes in treatment regimens if a loading dose is not used.
Studies in baboons to determine passage across the blood-brain barrier have shown that only small quantities of diflunisal, under normal or acidotic conditions are transported into the cerebrospinal fluid (CSF). The ratio of blood/CSF concentrations after intravenous doses of 50 mg/kg or oral doses of 100 mg/kg of diflunisal was 100:1. In contrast, oral doses of 500 mg/kg of aspirin resulted in a blood/CSF ratio of 5:1. Mild to Moderate Pain
DOLOBID is a peripherally-acting analgesic agent with a long duration of action. DOLOBID produces significant analgesia within 1 hour and maximum analgesia within 2 to 3 hours.
Consistent with its long half-life, clinical effects of DOLOBID mirror its pharmacokinetic behavior, which is the basis for recommending a loading dose when instituting therapy. Patients treated with DOLOBID, on the first dose, tend to have a slower onset of pain relief when compared with drugs achieving comparable peak effects. However, DOLOBID produces longer-lasting responses than the comparative agents.
Comparative single dose clinical studies have established the analgesic efficacy of DOLOBID at various dose levels relative to other analgesics. Analgesic effect measurements were derived from hourly evaluations by patients during eight and twelve-hour postdosing observation periods. The following information may serve as a guide for prescribing DOLOBID.
DOLOBID 500 mg was comparable in analgesic efficacy to aspirin 650 mg, acetaminophen 600 mg or 650 mg, and acetaminophen 650 mg with propoxyphene napsylate 100 mg. Patients treated with DOLOBID had longer lasting responses than the patients treated with the comparative analgesics.
DOLOBID 1000 mg was comparable in analgesic efficacy to acetaminophen 600 mg with codeine 60 mg. Patients treated with DOLOBID had longer lasting responses than the patients who received acetaminophen with codeine.
A loading dose of 1000 mg provides faster onset of pain relief, shorter time to peak analgesic effect, and greater peak analgesic effect than an initial 500 mg dose.
In contrast to the comparative analgesics, a significantly greater proportion of patients treated with DOLOBID did not remedicate and continued to have a good analgesic effect eight to twelve hours after dosing. Seventy-five percent (75%) of patients treated with DOLOBID continued to have a good analgesic response at four hours. When patients having a good analgesic response at four hours were followed, 78% of these patients continued to have a good analgesic response at eight hours and 64% at twelve hours. Chronic Anti-inflammatory Therapy in Osteoarthritis and Rheumatoid Arthritis
In the controlled, double-blind clinical trials in which DOLOBID (500 mg to 1000 mg a day) was compared with anti-inflammatory doses of aspirin (2-4 grams a day), patients treated with DOLOBID had a significantly lower incidence of tinnitus and of adverse effects involving the gastrointestinal system than patients treated with aspirin. (See also Effect on Fecal Blood Loss).
Osteoarthritis
The effectiveness of DOLOBID for the treatment of osteoarthritis was studied in patients with osteoarthritis of the hip and/or knee. The activity of DOLOBID was demonstrated by clinical improvement in the signs and symptoms of disease activity.
In a double-blind multicenter study of 12 weeks' duration in which dosages were adjusted according to patient response, DOLOBID, 500 or 750 mg daily, was shown to be comparable in effectiveness to aspirin, 2000 or 3000 mg daily. In open-label extensions of this study to 24 or 48 weeks, DOLOBID continued to show similar effectiveness and generally was well tolerated. Rheumatoid Arthritis
In controlled clinical trials, the effectiveness of DOLOBID was established for both acute exacerbations and long-term management of rheumatoid arthritis. The activity of DOLOBID was demonstrated by clinical improvement in the signs and symptoms of disease activity.
In a double-blind multicenter study of 12 weeks' duration in which dosages were adjusted according to patient response, DOLOBID 500 or 750 mg daily was comparable in effectiveness to aspirin 2,600 or 3,900 mg daily. In open-label extensions of this study to 52 weeks, DOLOBID continued to be effective and was generally well tolerated.
DOLOBID 500, 750, or 1000 mg daily was compared with aspirin 2000, 3000, or 4000 mg daily in a multicenter study of 8 weeks' duration in which dosages were adjusted according to patient response. In this study, DOLOBID was comparable in efficacy to aspirin.
In a double-blind multicenter study of 12 weeks' duration in which dosages were adjusted according to patient needs, DOLOBID 500 or 750 mg daily and ibuprofen 1600 or 2400 mg daily were comparable in effectiveness and tolerability.
In a double-blind multicenter study of 12 weeks' duration, DOLOBID 750 mg daily was comparable in efficacy to naproxen 750 mg daily. The incidence of gastrointestinal adverse effects and tinnitus was comparable for both drugs. This study was extended to 48 weeks on an open-label basis. DOLOBID continued to be effective and generally well tolerated.
In patients with rheumatoid arthritis, DOLOBID and gold salts may be used in combination at their usual dosage levels. In clinical studies, DOLOBID added to the regimen of gold salts usually resulted in additional symptomatic relief but did not alter the course of the underlying disease.
Antipyretic Activity
DOLOBID is not recommended for use as an antipyretic agent. In single 250 mg, 500 mg, or 750 mg doses, DOLOBID produced measurable but not clinically useful decreases in temperature in patients with fever; however, the possibility that it may mask fever in some patients, particularly with chronic or high doses, should be considered. Uricosuric Effect
In normal volunteers, an increase in the renal clearance of uric acid and a decrease in serum uric acid was observed when DOLOBID was administered at 500 mg or 750 mg daily in divided doses. Patients on long-term therapy taking DOLOBID at 500 mg to 1000 mg daily in divided doses showed a prompt and consistent reduction across studies in mean serum uric acid levels, which were lowered as much as 1.4 mg%. It is not known whether DOLOBID interferes with the activity of other uricosuric agents. Effect on Platelet Function
As an inhibitor of prostaglandin synthetase, DOLOBID has a dose-related effect on platelet function and bleeding time. In normal volunteers, 250 mg b.i.d. for 8 days had no effect on platelet function, and 500 mg b.i.d., the usual recommended dose, had a slight effect. At 1000 mg b.i.d., which exceeds the maximum recommended dosage, however, DOLOBID inhibited platelet function. In contrast to aspirin, these effects of DOLOBID were reversible, because of the absence of the chemically labile and biologically reactive 0-acetyl group at the carbon 4 position. Bleeding time was not altered by a dose of 250 mg b.i.d., and was only slightly increased at 500 mg b.i.d. At 1000 mg b.i.d., a greater increase occurred, but was not statistically significantly different from the change in the placebo group.
Effect on Fecal Blood Loss
When DOLOBID was given to normal volunteers at the usual recommended dose of 500 mg twice daily, fecal blood loss was not significantly different from placebo. Aspirin at 1000 mg four times daily produced the expected increase in fecal blood loss. DOLOBID at 1000 mg twice daily (NOTE: exceeds the recommended dosage) caused a statistically significant increase in fecal blood loss, but this increase was only one-half as large as that associated with aspirin 1300 mg twice daily. Effect on Blood Glucose
DOLOBID did not affect fasting blood sugar in diabetic patients who were receiving tolbutamide or placebo.
|
